Floralis   Report issue

For profit Phase 3
Founded: Grenoble France (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2020
NCT04431999
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Floralis

Active Ingredients

Drugs in Phase 3 Trials (4)

autologous plasma (1 trial)

platelets (1 trial)

red blood cells (1 trial)

whole blood (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blood Coagulation Disorders (Phase 3)

Hemorrhage (Phase 3)

Hemostatic Disorders (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 4